U.S. Retail Distributors Stock News

NYSE:ED
NYSE:EDIntegrated Utilities

How Investors Are Reacting To Consolidated Edison (ED) Raising Equity To Fund Grid And Clean Energy Upgrades

In February 2026, Consolidated Edison completed a follow-on equity offering of 7,000,000 common shares via a forward sale agreement with JPMorgan, raising about US$775.67 million to support subsidiary capital needs and general corporate purposes. This equity raise underpins Con Edison’s plan to invest about US$38.00 billion in grid upgrades and clean-energy-related infrastructure over the next five years amid rising electrification demand. Next, we’ll examine how this sizeable equity...
NYSE:KR
NYSE:KRConsumer Retailing

Kroger CEO Shift To Greg Foran Puts Restructuring In Sharper Focus

Kroger (NYSE:KR) appointed Greg Foran, a former Walmart executive, as its new CEO following a board investigation. The appointment comes after the resignation of former CEO Rodney McMullen over an ethics violation. Kroger is pursuing cost cuts, a leaner structure, and closing underperforming stores as part of a broader restructuring effort. Kroger, trading at $68.24, is entering this leadership change after a multi year period in which the stock has delivered 58.6% over 3 years and 120.3%...
NasdaqGS:SFD
NasdaqGS:SFDFood

Smithfield Foods Sioux Falls Expansion Draws Focus To Costs And Valuation

Smithfield Foods, NasdaqGS:SFD, plans to build a new packaged meats and fresh pork processing facility in Sioux Falls, South Dakota. The new facility is intended to replace the company’s historic existing plant in the city. The expansion is aimed at improving operational efficiency and supporting the surrounding agricultural community. For investors following NasdaqGS:SFD, this project comes with the stock trading at $24.88 and a return of 24.9% over the past year. That kind of move often...
NasdaqGS:PLTK
NasdaqGS:PLTKEntertainment

Why Playtika (PLTK) Is Down 11.0% After 2025 Loss, 2026 Outlook And Capital Shift

Recently, Playtika Holding Corp. reported full-year 2025 results showing revenues of US$2.76 billion and a net loss of US$206.4 million, while issuing 2026 revenue guidance of US$2.70 billion to US$2.80 billion alongside a refinancing of its US$550 million revolving credit facility. Beneath the headline loss, the company highlighted record free cash flow, strong growth from direct-to-consumer channels and casual games, and a shift in capital allocation by suspending its dividend to...
NYSE:AA
NYSE:AAMetals and Mining

Alcoa (AA) Valuation Check After Dividend, Cost Cuts And Alumina Acquisition Shift Market Sentiment

Alcoa (AA) is back in focus after its board declared a quarterly cash dividend of $0.10 per share, payable on March 26, 2026, reinforcing the company’s current shareholder return profile. See our latest analysis for Alcoa. At a share price of $61.87, Alcoa has had a 48.23% 90 day share price return and an 88.46% 1 year total shareholder return. This suggests momentum has been building as short interest falls and investors weigh dividend continuity alongside recent integration and cost...
NYSE:SJM
NYSE:SJMFood

Is J. M. Smucker (SJM) Pricing Reflect Its DCF Upside After Recent Share Price Rebound

If you are wondering whether J. M. Smucker is fairly priced at around US$115.95 or offering value, this article will walk through what the numbers actually say about the stock. The share price has moved by 5.0% over the last 7 days, 12.2% over the last 30 days, 20.0% year to date, 9.1% over 1 year, and shows a 14.2% decline over 3 years and a 15.8% return over 5 years. This provides useful context before comparing it to underlying value. Recent news coverage around J. M. Smucker has focused...
NYSE:LOB
NYSE:LOBBanks

Does Live Oak Bancshares’ (LOB) Dividend Mix Reveal Its Evolving Small-Business Banking Strategy?

On February 19, 2026, Live Oak Bancshares’ board declared a US$0.03 per share common dividend and a US$0.52344 per Series A preferred depositary share dividend, both payable on March 15, 2026 to shareholders of record on March 5, 2026. The simultaneous affirmation of common and higher-yielding preferred dividends underscores management’s current confidence in the bank’s capital position despite recent macro-driven pressure on regional lenders. With inflation concerns weighing on regional...
NYSE:T
NYSE:TTelecom

The Bull Case For AT&T (T) Could Change Following Its New Critical Infrastructure Alliance Role

AT&T, as a founding member of the newly launched Alliance for Critical Infrastructure, has joined an industry-led nonprofit coalition aimed at strengthening national resilience through greater collaboration and information sharing among critical infrastructure owners and operators. This move positions AT&T closer to the center of cross-industry risk management and crisis response efforts at a time when infrastructure security remains a priority for governments, regulators, and large...
NasdaqGM:ANIP
NasdaqGM:ANIPPharmaceuticals

ANI Pharmaceuticals (ANIP) Profitability Turn In Q4 2025 Tests Premium P/E Narrative

ANI Pharmaceuticals (ANIP) just posted fourth quarter FY 2025 revenue of US$247.1 million with basic EPS of US$1.56, capping a trailing twelve month stretch that saw revenue reach US$883.4 million and basic EPS of US$3.85. The company has seen revenue move from US$190.6 million and basic EPS of a US$0.55 loss in Q4 2024 to US$247.1 million and US$1.56 in Q4 2025, while trailing twelve month EPS shifted from a US$1.04 loss to a US$3.85 profit as margins turned positive. For investors, this set...
NasdaqGM:PRCT
NasdaqGM:PRCTMedical Equipment

PROCEPT BioRobotics Resets Commercial Model To Pursue Higher Quality Growth

PROCEPT BioRobotics (NasdaqGM:PRCT) has overhauled its commercial model, implementing a major realignment of its sales organization and pricing strategy. The company has removed bulk purchase discounts and created a dedicated team focused on driving greater procedural adoption. These changes come alongside significant procedure growth and a reset in financial guidance, marking a key shift in how the company pursues profitability and market expansion. PROCEPT BioRobotics focuses on robotic...
NYSE:PNR
NYSE:PNRMachinery

A Look At Pentair (PNR) Valuation After Recent Share Price Softness

Pentair stock overview after recent performance Pentair (PNR) has seen its share price soften recently, with a 1 day return of about a 1.2% decline and a month return near a 5.7% decline. The past 3 months show similar pressure on the stock. See our latest analysis for Pentair. At around US$99.19, Pentair’s recent share price pressure, including a 5.9% year to date share price decline, sits against a contrasting backdrop of a 6.4% 1 year total shareholder return and an 83.5% 5 year total...
NYSE:AXTA
NYSE:AXTAChemicals

Axalta Coating Systems (AXTA) Valuation Check After Recent Share Price Cooling

Why Axalta Coating Systems Is On Investors’ Radar Today Axalta Coating Systems (AXTA) has drawn investor attention after recent trading left the stock with mixed short term returns, including a 0.6% decline over the past day and 3.1% over the past week. See our latest analysis for Axalta Coating Systems. That recent 3.1% 7 day share price decline and 1.9% 30 day share price pullback sit against a 10.9% 90 day share price gain, while the 1 year total shareholder return of 7.7% decline...
NasdaqGS:PAYX
NasdaqGS:PAYXProfessional Services

Paychex (PAYX) Valuation Check After New AI Features Across Paycor And Paychex Flex Platforms

Paychex (PAYX) is in focus after unveiling new AI-driven features across its Paycor and Paychex Flex platforms, including Paycor Smart Scheduler and expanded automation for time and attendance workflows. See our latest analysis for Paychex. Despite the AI rollout, Paychex’s recent share price performance has been weak, with a 30 day share price return of 8.59% and a year to date share price return of 13.77%. In contrast, the 1 year total shareholder return of 36.08% points to pressure...
NYSE:Q
NYSE:QSemiconductor

Qnity Electronics Weighs M&A Pipeline And $500m Buybacks As Valuation Stretches

Qnity Electronics (NYSE:Q) is pursuing an active M&A pipeline to expand its portfolio following recent strong financial results. The company recently announced a $500 million share repurchase program alongside ongoing product development. The combination of buybacks, new products and targeted acquisitions marks a meaningful shift in how Qnity Electronics is using its balance sheet. For shareholders watching Qnity Electronics at a current share price of $126.76, this new focus on M&A sits on...
NasdaqGM:LUNR
NasdaqGM:LUNRAerospace & Defense

Intuitive Machines Equity Raise Fuels Lunar Network Ambitions And Dilution Questions

Intuitive Machines, ticker NasdaqGM:LUNR, has secured a $175 million equity investment from global institutional investors via a private placement. The funding is intended to accelerate lunar and deep space communications projects, including satellite networks and advanced data processing. This capital raise follows the recent acquisition of Lanteris and is aimed at building a "solar system internet" linking Earth, the Moon, and Mars. The transaction introduces additional capital for growth...
NYSE:PSX
NYSE:PSXOil and Gas

Is Phillips 66’s Direct Venezuelan Crude Move And Higher Dividend Altering The Investment Case For PSX?

In February 2026, Phillips 66 sought U.S. approval to buy heavy crude directly from Venezuela’s PDVSA from April, while also lifting its quarterly dividend to reinforce its shareholder return framework. By moving to bypass intermediaries in sourcing Venezuelan crude, Phillips 66 is aiming to sharpen feedstock economics and underpin its capacity to fund ongoing dividend growth. We’ll now examine how the shift to direct Venezuelan crude sourcing could influence Phillips 66’s investment...
NYSE:HUM
NYSE:HUMHealthcare

Humana (HUM) Valuation Check After Prolonged Share Price Weakness And Regulatory Scrutiny

Humana stock performance snapshot Humana (HUM) has seen mixed share performance recently, with the stock down over the past month and past 3 months, and also negative on a 1 year and longer term total return basis. At a last close of US$190.54, the health insurer and senior care provider reports annual revenue of about US$129.7b and net income of US$1.19b. See our latest analysis for Humana. Humana's share price has seen a modest 1 day gain and a slight 7 day rise, but these moves sit against...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis

Recursion Pharmaceuticals reported its first positive clinical proof-of-concept for REC-4881 in familial adenomatous polyposis. The company hit a fifth collaboration milestone with Sanofi tied to its AI driven drug discovery platform. Management extended the cash runway into early 2028, reinforcing funding visibility for ongoing programs. For investors watching NasdaqGS:RXRX, this mix of clinical and partnership progress comes alongside a share price of $3.67 and a 1-year return...
NYSE:AMR
NYSE:AMRMetals and Mining

Alpha Metallurgical Resources FY 2025 Loss Deepens Narrative Rift On Turnaround Forecasts

Alpha Metallurgical Resources (AMR) has wrapped up FY 2025 with fourth quarter revenue of US$520.5 million and a basic EPS loss of US$1.34, while trailing twelve month figures show revenue of about US$2.1 billion and a basic EPS loss of US$4.75. Over the past few quarters, revenue has moved from US$617.3 million in Q4 2024 to US$520.5 million in Q4 2025, with quarterly EPS shifting from a loss of US$0.16 in Q4 2024 to a loss of US$1.34 in Q4 2025. Investors may weigh the recent margin trends...
NYSE:CNK
NYSE:CNKEntertainment

Cinemark (CNK) Is Up 6.4% After Soft Q4 But Steady Capital Returns - Has The Bull Case Changed?

Cinemark Holdings has already reported fourth-quarter 2025 results showing revenue of US$776.3 million and net income of US$34.1 million, alongside full-year 2025 revenue of US$3.12 billion and net income of US$138.2 million. Despite lower quarterly earnings than the prior year, Cinemark’s board maintained a US$0.09 quarterly dividend and completed a US$75 million share repurchase of 3,136,810 shares, signaling continued capital returns. We’ll now examine how Cinemark’s latest earnings...
NasdaqGS:EXTR
NasdaqGS:EXTRCommunications

A Look At Extreme Networks (EXTR) Valuation After Recent Share Price Weakness

How Extreme Networks stock has been performing Extreme Networks (EXTR) has drawn attention after a period of weaker share performance, with the stock showing a 7% decline over the past month and a 20.1% decline over the past 3 months. Over a longer horizon, the shares show a 15.5% decline year to date and a 9.5% decline over the past year, alongside a 3 year total return decline of 22.9% and a 5 year total return of 71.3%. For context, the company recently reported annual revenue of US$1.22b...
NasdaqGS:DSGR
NasdaqGS:DSGRTrade Distributors

Assessing Distribution Solutions Group (DSGR) Valuation After Recent Share Price Moves

Why Distribution Solutions Group Is On Watch Today Distribution Solutions Group (DSGR) is back on investor radars after recent share price moves, with the stock closing at $29.92 and showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Distribution Solutions Group. Looking beyond the latest close at $29.92, Distribution Solutions Group has seen a 6.78% 1 month share price return and a 6.70% year to date share price return. The 3 year total...
NasdaqGS:STX
NasdaqGS:STXTech

Is It Too Late To Consider Seagate Technology Holdings (STX) After Its 308% One Year Surge?

If you are wondering whether Seagate Technology Holdings is still reasonably priced after its run in the spotlight, you are in the right place to get a clear view of what you might be paying for. The stock last closed at US$407.84, with a 0.8% decline over the past 7 days and a 7.9% decline over the past 30 days, while showing a 41.8% return year to date and a 1 year return of 308%, and 3 and 5 year returns that are also very large. Recent coverage around Seagate has focused on its role in...
NasdaqGM:MIRM
NasdaqGM:MIRMBiotechs

Mirum Broadens Rare Disease Portfolio With Bluejay Deal And New Approvals

Mirum Pharmaceuticals acquired Bluejay Therapeutics, adding worldwide rights to brelovitug for hepatitis delta virus. The company gained new regulatory approvals, including etexlate for CTX and a tablet formulation of Livmarli. These updates expand Mirum's clinical pipeline and product lineup beyond its prior focus areas. Mirum Pharmaceuticals, traded as NasdaqGM:MIRM, is drawing attention with this mix of pipeline expansion and regulatory progress. The stock trades at $92.29, with a 1 year...